The short synacthen test (SST) is widely used in diagnosing adrenal insufficiency as a safer and cheaper alternative to the insulin tolerance test (ITT). Following administration of synacthen, serum cortisol concentration is measured at 30 and 60 min. Despite its widespread use, consensus lacks among physicians regarding the additional value of the 60 min sample. Furthermore, only the 30 min value has been validated against ITT.
In this large (n ¼ 384) retrospective study, Chitale et al. report on the utility of measuring serum cortisol at 60 min in addition to the sample at 30 min. The aim was to determine the frequency of misdiagnosis if a 60 min sample was not taken. Several groups were excluded: patients taking corticosteroids not omitted before SST, patients taking oestrogens; patients with congenital adrenal hyperplasia or chronic liver disease and pregnant women. Serum cortisol was measured 0, 30 and 60 min after intravenous or intramuscular synacthen (250 mg) using Advia-Centaur or Roche-Elecsys immunoassays. Patients 'passed' if the cortisol concentration was 550 nmol/L at 30 and 60 min or 'failed' if cortisol was ,550 nmol/L at both time points. A partial pass was defined as 30 min cortisol 550 nmol/L and 60 min ,550 nmol/L and delayed response as 30 min cortisol ,550 nmol/L and 60 min 550 nmol/L. All 75 individuals insufficient at 60 min were also insufficient at 30 min; none had a partial pass and 33 patients had a delayed response. In the latter group, the mean cortisol was 232 nmol/L (+104), 486 nmol/L (+29) and 588 nmol/L (+27) at the three time points.
The 60 min cortisol was superior as a gold standard versus the 30 min test (higher specificity, positive predictive value, ROC area). In this study 11% of patients undergoing SST would be inappropriately diagnosed with adrenal insufficiency had the 60 min sample not been used. In view of biological and analytical variation, it is recommended that each laboratory should use their own results validated at the three time points.
In conclusion, routinely taking a 60 min sample would improve the specificity of SST and avoid misdiagnosis of adrenal insufficiency. This revised classification document attempts to provide a universal system for categorizing the type and severity of acute pancreatitis. It also addresses shortcomings of the original 1992 guidelines that have emerged with improved understanding of disease pathogenesis. New definitions of early and late disease status are provided in addition to criteria for mild, moderate and severe acute pancreatitis.
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The revised criteria defines diagnosis of acute pancreatitis as the presence of two of the following criteria: (i) abdominal pain consistent with acute pancreatitis, (ii) serum lipase or amylase activity greater than three times the upper limit of normal and (iii) characteristic findings on contrastenhanced computed tomography (CECT). The type (interstitial oedematous pancreatitis or necrotizing pancreatitis) and presence of local complications are also assessed by CECT.
The main determinant of severity classification is the presence and duration of organ failure. Of note, the APACHE II and Ranson scoring systems (which include electrolyte, lactate dehydrogenase, alanine transaminase and acidbase analysis) are no longer recommended for assessing severity. Rather, the modified Marshall scoring system is used to subjectively define organ failure based on simple assessments of renal, cardiovascular and respiratory function. Within this system, cardiovascular and respiratory function scores are largely provided by clinical assessment while renal dysfunction is scored on extent of serum creatinine increase above 134 mmol/L. This single scoring system approach should eliminate much of the confusion associated with categorizing disease severity; however, it fails to define criteria for patients with pre-existing renal disease and baseline creatinine above 134 mmol/L.
Overall the revised classification represents a shift from biochemical testing to radiological imaging for assessment of acute pancreatitis. However, pancreatic enzyme analysis is recommended as part of the initial diagnosis, and subsequent computed tomography imaging should only be conducted when there is high clinical suspicion of acute pancreatitis in the absence of significant enzyme elevation.
